The grant provides Imaging Biometrics with income for five years, money which it will use to further develop its brain tumour software
’s () Imaging Biometrics subsidiary has received a US$2.75mln, five-year grant from the US Department of Health’s National Cancer Institute.
Imaging Biometrics will use the money to develop more software solutions that can help doctors better understand and treat advanced brain tumours.
Its Rad Tech software was used last year in a big US clinical trial to quantify how patients were responding to Avastin – a common cancer medication.
“Our grant and contract development work are important stimuli at Imaging Biometrics,” said IB’s chief executive David Smith.
“This grant will provide income for the company for the next five years, as well as, further catalyse the development of our quantitative imaging tools, enabling us to apply the result of this collaboration with MCW to our commercial products.”
IQ-AI shares were up 7.8% to 6.25p on Wednesday morning, valuing the company at £8.4mln.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE